scispace - formally typeset
A

Alberto Anel

Researcher at University of Zaragoza

Publications -  146
Citations -  12316

Alberto Anel is an academic researcher from University of Zaragoza. The author has contributed to research in topics: Cytotoxic T cell & Apoptosis. The author has an hindex of 43, co-authored 132 publications receiving 11097 citations. Previous affiliations of Alberto Anel include Stanford University & National Scientific and Technical Research Council.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

How Do Cytotoxic Lymphocytes Kill Cancer Cells

TL;DR: The two main pathways involved in CL-mediated tumor cell death, granule exocytosis (perforin and granzymes) and death ligands, are briefly introduced, followed by a critical discussion of the molecules involved in cell death during cancer immunosurveillance and immunotherapy.
Journal ArticleDOI

Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB.

TL;DR: FFA levels increased, for the same chain length, with increasing degree of acyl chain unsaturation, suggesting that FA aqueous solubility may play a significant role in the equilibrium between FA association with albumin and the aqueously phase.
Journal Article

Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.

TL;DR: It is shown that upon mitogenic stimulation, bioactive FasL and APO2L are released from the T cell leukemia Jurkat and from normal human T cell blasts as intact, nonproteolyzed proteins associated with a particulate, ultracentrifugable fraction that provides the basis for a new and efficient mechanism for the rapid induction of autocrine or paracrine cell death during immune regulation.
Journal ArticleDOI

Onto better TRAILs for cancer treatment

TL;DR: This review summarizes these second-generation novel formulations of TRAIL and other TRAIL-R agonists, which exhibit enhanced cytotoxic capacity toward cancer cells, thereby providing the potential of being more effective when applied clinically than first-generation TRAil- R agonists.